DelSite Presents New Data on GelSite® Nasal Powder Delivery System at Controlled Release Society Meeting
Share:
GelSite® Polymer Has a Distinct Chemical and Biological Function Uniquely Suited to Meet the Challenges Faced in a Pandemic Flu
IRVING, Texas, July 26 // -- Carrington Laboratories, Inc. (NASDAQ:CARN) today announced that Dr. Paul Stroud, Director of Polymer Research and Development at DelSite Biotechnologies, Inc., Carrington's wholly-owned subsidiary, presented the latest findings on the GelSite® nasal powder delivery system for proteins and peptides at the 33rd Annual Meeting of the Controlled Release Society held in Vienna, Austria.
The delivery system's key component is the GelSite® polymer, which provides gelling and mucoadhesion properties allowing for prolonged nasal residence time and sustained release of potential peptide/protein therapeutics to the circulation and central nervous system. Data suggest that this delivery system can be formulated to allow for interactions between the polymer and peptides/proteins for enhanced stability, which adds an additional means of controlled release in developing formulations for optimal delivery of vaccines and therapeutics.
Carlton E. Turner, CEO of Carrington and DelSite, said, "Dr. Stroud's work on the GelSite® polymer nasal powder drug delivery platform represents a novel and efficient approach for nasal drug delivery. It is not only suitable for drugs for local actions, but also those with systemic effects. In addition, the platform can possibly provide rapid absorption and onset of pharmacological activity, avoidance of some liver metabolism, an easy and fast route of administration, and the possibility of an efficient pathway to deliver therapeutics across the brain barrier. These factors make this delivery platform rather fascinating."
Turner continued, "The GelSite polymer is also highly suited for injectable administration. The value of stabilization and controlled delivery of therapeutics was the driving force for the recent technology development agreement with Brookwood Pharmaceuticals for development of injectable applications using GelSite® polymer."
About GelSite® Polymer
GelSite® polymer is being developed as a controlled-release drug delivery technology for pharmaceutical and vaccine products:
o GelSite® is the core polymer used in the GelVac(TM) nasal powder
delivery system.
o GelSite® polymer has distinct chemical and biological functions
uniquely suited to meet the challenges faced for pandemic flu needs.
o GelSite® polymer can be produced in kilogram quantities greater than
99% pure
About DelSite
DelSite Biotechnologies, Inc. is a wholly-owned subsidiary of Carrington and was formed based on discoveries at Carrington. DelSite is a drug delivery and biotechnology company established to provide the pharmaceutical and biotechnology industries with novel delivery solutions for vaccines and therapeutic agents.
About Carrington
Carrington Laboratories, Inc. is an ISO 9001-certified, research-based, biopharmaceutical and consumer products company currently utilizing naturally- occurring complex carbohydrates to manufacture and market products for mucositis, radiation dermatitis, wound and oral care, as well as to manufacture and market the nutraceutical raw material Manapol® and cosmetic raw material Hydrapol(TM). Carrington also manufactures and markets consumer products and manufactures quality products for other companies. Manufacturing operations comply with cGMP standards. Carrington's technology is protected by more than 130 patents in 26 countries. Select products carry the CE mark, recognized by more than 20 countries around the world. For more information, visit www.carringtonlabs.com.
Source: Carrington Laboratories, Inc.
CONTACT:
Carlton E. Turner,
Chief Executive Officer,
Carrington Laboratories, Inc.,
Tel:+1-972-518-1300
Web site: www.carringtonlabs.com/
